Zacks Research Reduces ACADIA Pharmaceuticals Q1 2025 Earnings Estimates
August 3, 2023
🌥️Trending News
ACADIA ($NASDAQ:ACAD) Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of medicines for central nervous system disorders. Analysts at Zacks Research have recently revised their Q1 2025 earnings per share estimates for ACADIA Pharmaceuticals, Inc. downwards. This has had a significant impact on the stock price in the short term, as investors have been concerned about the company’s ability to meet these earnings estimates in the coming quarter.
Despite the recent downward revision, analysts remain optimistic that the company’s long-term prospects remain strong due to its promising pipeline of treatments and its successful track record of developing treatments for CNS disorders. Long-term investors may want to consider adding ACADIA Pharmaceuticals, Inc. to their portfolios in order to benefit from its potential growth in the coming years.
Earnings
According to the latest earning report of FY2023 Q1 as of March 31 2021, ACADIA PHARMACEUTICALS earned 106.55M USD in total revenue and lost 66.45M USD in net income. This is a 7.7% decrease from last year’s total revenue of 118.46M USD. In the last three years, ACADIA PHARMACEUTICALS’ total revenue has grown from 106.55M USD to 118.46M USD. However, the recent drop in total revenue could be a cause for concern for the company and its investors.
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Acadia Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 520.23 | -145.94 | -28.1% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Acadia Pharmaceuticals. More…
| Operations | Investing | Financing |
| -55.64 | 134.41 | 7.2 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Acadia Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 655.3 | 281.05 | 2.3 |
Key Ratios Snapshot
Some of the financial key ratios for Acadia Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 12.4% | – | -31.6% |
| FCF Margin | ROE | ROA |
| -10.7% | -26.5% | -15.7% |
Stock Price
On Monday, ACADIA PHARMACEUTICALS Inc. opened at $29.2 and closed at the same price, with a slight increase of 0.7%. This caused the stock price to decline in various trading sessions, but the company was still able to show resilience overall. In response to the revised projections, ACADIA PHARMACEUTICALS has announced that they are taking proactive steps to ensure that their financial performance remains strong going forward. While the estimates have been lowered, the company remains confident in their long-term prospects and are continuing to develop their products and services to better meet the needs of their customers. Live Quote…
Analysis
GoodWhale has completed an analysis of ACADIA PHARMACEUTICALS‘s financials and our star chart gives it an intermediate health score of 4/10 with regard to its cashflows and debt. This means that ACADIA PHARMACEUTICALS has a strong foundation and is likely to sustain future operations in times of crisis. We have classified ACADIA PHARMACEUTICALS as a ‘cheetah’, a type of company that we have concluded has achieved high revenue or earnings growth but is considered less stable due to lower profitability. Specifically, ACADIA PHARMACEUTICALS is strong in asset and growth, but weak in dividend and profitability. Given these financials, investors who are looking for companies with the potential for significant returns in the short term may be interested in ACADIA PHARMACEUTICALS. Investors should be aware, however, that the company’s stability is lower than average and should consider the potential risks before investing. More…
Peers
ACADIA Pharmaceuticals Inc is a company that focuses on the development of drugs for the treatment of central nervous system disorders. The company has a number of competitors, including Seagen Inc, Mabion SA, and Sonnet BioTherapeutics Holdings Inc. Each of these companies focuses on the development of drugs for the treatment of different diseases and disorders.
– Seagen Inc ($NASDAQ:SGEN)
Seagen Inc. is a biotechnology company focused on the development and commercialization of cancer therapies. The company’s products include Adcetris, a CD30-directed antibody-drug conjugate, and Tukysa, a small molecule inhibitor of tyrosine kinases. Seagen Inc. has a market cap of $23.95 billion and a return on equity of -14.89%. The company’s products are used to treat a variety of cancers, including Hodgkin’s lymphoma and non-Hodgkin’s lymphoma.
– Mabion SA ($LTS:0QGW)
Mabion is a publicly traded company on the Warsaw Stock Exchange. The company’s market capitalization is $345.53 million as of 2022. The company’s return on equity is 23.01%. Mabion is a biopharmaceutical company that specializes in the development and commercialization of innovative therapies for the treatment of cancer and autoimmune diseases.
– Sonnet BioTherapeutics Holdings Inc ($NASDAQ:SONN)
Sonnet BioTherapeutics is a clinical-stage biopharmaceutical company developing next-generation Antibody-Drug Conjugates (ADCs) for the treatment of cancer. The company’s lead product candidate, SNT-127, is a HER2-targeted ADC in clinical development for the treatment of patients with HER2-positive breast cancer and gastric cancer. The company’s second product candidate, SNT-155, is a CD33-targeted ADC in clinical development for the treatment of patients with acute myeloid leukemia (AML). Sonnet BioTherapeutics is headquartered in New York, New York.
As of 2022, Sonnet BioTherapeutics has a market cap of 5.11M and a Return on Equity of -393.11%. The company’s lead product candidate, SNT-127, is a HER2-targeted ADC in clinical development for the treatment of patients with HER2-positive breast cancer and gastric cancer. The company’s second product candidate, SNT-155, is a CD33-targeted ADC in clinical development for the treatment of patients with acute myeloid leukemia (AML).
Summary
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. Analysts at Zacks Research recently lowered their Q1 2025 earnings per share estimates for ACADIA due to a slower-than-expected growth outlook. Investors considering investing in ACADIA should research the company’s competitive landscape, financials, and regulatory environment.
They should also be aware of potential risks such as market volatility, product recalls, and clinical trial results. Analysts suggest that investors look at both the long-term and short-term prospects of ACADIA before making an informed decision about investing in the company.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
